Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases.

Journal of viral hepatitis·2014
Same author

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial.

Alimentary pharmacology & therapeutics·2004
Same author

Transplantation of livers from hbc Ab positive donors into HBc Ab negative recipients: a strategy and preliminary results.

Clinical transplantation·2002
Same author

Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia?

Hepatology (Baltimore, Md.)·2001
Same author

Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease.

Gastroenterology·2001
Same author

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

Hepatology (Baltimore, Md.)·2001

Related Experiment Video

Updated: May 11, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Interferon for hepatitis B: US experience

R P Perrillo1

  • 1Gastroenterology Section, Veterans Administration Medical Center, St Louis, Missouri 63106.

Gut
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Treatment with interferon alfa-2b for chronic hepatitis B showed significant HBeAg and HBV-DNA loss. Long-term follow-up suggests potential for terminating the hepatitis B virus carrier state.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Experiment Videos

Last Updated: May 11, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Chronic hepatitis B virus (HBV) infection affects millions globally.
  • Effective antiviral therapies are crucial for managing HBV infection and preventing complications.
  • Interferon alfa-2b has been investigated as a treatment option for chronic hepatitis B.

Purpose of the Study:

  • To review recent US studies on interferon alfa-2b treatment for chronic hepatitis B.
  • To evaluate the efficacy and outcomes of interferon alfa-2b therapy in patients with chronic hepatitis B.

Main Methods:

  • Review of US multicentre and National Institutes of Health (NIH) trials.
  • Treatment regimens involved interferon alfa-2b at different dosages and frequencies (5 MU daily vs. 10 MU thrice weekly) for 16 weeks.
  • Assessment of hepatitis B e antigen (HBeAg) and HBV-DNA loss, alongside virological, biochemical, histological, and clinical parameters.

Main Results:

  • HBeAg and HBV-DNA loss observed in 37% (5 MU daily) and 42% (10 MU thrice weekly) of patients.
  • Loss of HBeAg and HBV-DNA correlated with significant improvements in virological, biochemical, histological, and clinical outcomes.
  • Long-term follow-up in the NIH study revealed HBsAg disappearance in 65% of responders over four years.

Conclusions:

  • Interferon alfa-2b therapy is effective in achieving virological and biochemical responses in chronic hepatitis B.
  • The observed HBsAg clearance suggests a potential for eradicating the hepatitis B virus carrier state.
  • Further research and long-term monitoring are warranted to confirm sustained responses and potential cure.